Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

Danish group’s shares rise after it cuts cost for blockbuster diabetes and weight-loss drug for patients without insurance ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

The Ozempic price cut could appease US President Donald Trump, who has pushed for drug companies to lower their prices.

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...